(NBC) AstraZeneca has started Phase 3 clinical testing of its coronavirus vaccine candidate in the U.S.
The British drugmaker says the trial will enroll up to 30,000 adults at 80 sites across the country.
Two-thirds of the study participants will receive two doses of the experimental vaccine, given four weeks apart. The rest will receive a placebo.
The company says results are expected later this year.
The vaccine candidate, known as AZD1222, is made in partnership with England’s University of Oxford.
© 2024 KOBI-TV NBC5. All rights reserved unless otherwise stated.